Pfizer's COVID Drug Data Supports Use in High-Risk Patients: FDA Staff
The US health regulator's staff reviewers said on Tuesday data from Pfizer's COVID-19 drug trials support its use in adults at high risk of progressing to severe disease, bringing the pill closer to a full approval.
Reuters Health Information
source https://www.medscape.com/viewarticle/989613?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/989613?src=rss
Comments
Post a Comment